Monitor the first few days of trading for price stabilization and volume patterns. Key catalysts ahead include data from the MIST Phase 2b trial for AP01 and the AURA Phase 2 trial for AP02. The $300M raise provides a multi-year cash runway through these readouts.
Price Chart
Executive Summary
Avalyn Pharma priced its upsized IPO of 16,666,667 shares at $18.00/share, raising $300M in gross proceeds. The clinical-stage biopharma is advancing inhaled therapies for pulmonary fibrosis, with two Phase 2 trials ongoing. The offering provides substantial capital to fund development through key data readouts.
Key Financial Metrics
Key Facts
- IPO of 16,666,667 shares priced at $18.00/share
- Gross proceeds of $300M
- Underwriters have 30-day option for additional 2,500,000 shares
- Shares expected to trade on Nasdaq under AVLN starting April 30, 2026
- Lead underwriters: Morgan Stanley, Jefferies, Evercore ISI, Guggenheim Securities
- Company is clinical-stage with AP01 (Phase 2b for PPF) and AP02 (Phase 2 for IPF) programs
Financial Impact
$300M gross proceeds from IPO
Risk Factors
- Clinical-stage biotech with no approved products or revenue
- Phase 2 trial failures could wipe out value
- Dilution from IPO and potential future offerings
- Competitive landscape includes oral pirfenidone and nintedanib generics
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3284397 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 21, 2026 5w ago | Press Release | $31.62 $28.32 | ▼ −10.44% | ▼ −9.42% | $27.14 (−14.17%) |
Aug 16, 2026 10w ago | Institutional Cluster | $38.25 $37.69 | ▼ −1.46% | ▼ −0.27% | $27.14 (−29.05%) |
Aug 12, 2026 10w ago | 8-K | $37.38 $38.97 | ▲ +4.25% | ▲ +4.70% | $27.14 (−27.39%) |
Aug 12, 2026 10w ago | Press Release | $37.38 $38.97 | ▲ +4.25% | ▲ +4.70% | $27.14 (−27.39%) |
Jun 17, 2026 18w ago | 8-K | $29.31 $30.09 | ▲ +2.66% | ▲ +3.70% | $27.14 (−7.40%) |
Jun 17, 2026 18w ago | Press Release | $29.31 $30.09 | ▲ +2.66% | ▲ +3.70% | $27.14 (−7.40%) |
Jun 3, 2026 20w ago | 8-K | $26.40 $28.53 | ▲ +8.07% | ▲ +11.89% | $27.14 (+2.80%) |
May 5, 2026 24w ago | Press Release | $27.71 $29.90 | ▲ +7.90% | ▲ +6.77% | $27.14 (−2.06%) |
May 1, 2026 25w ago | Insider Cluster | $29.07 $29.57 | ▲ +1.72% | ▼ −1.25% | $27.14 (−6.64%) |
May 1, 2026 25w ago | Insider Cluster | $29.07 $29.57 | ▲ +1.72% | ▼ −1.25% | $27.14 (−6.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers